No Data
Cipher Pharmaceuticals Says Partner Moberg's Phase 3 Nail Fungus Study Did Not Meet Primary Endpoint
Cipher Pharmaceuticals Inc (CPHRF) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
Press Release: Cipher Pharmaceuticals Reports Third Quarter 2024 Results
Press Release: Cipher Pharmaceuticals Enhances Leadership Team With Appointment of New Chief Business Officer
Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results
Cipher Pharmaceuticals Brief: Vice President, Finance Ryan Mailling Appointed as Chief Financial Officer
No Data